The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Open accessAbstract
Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present, a liver biopsy is the only generally acceptable method for the diagnosis of NASH and assessment of its progression toward cirrhosis. Although several treatments have shown evidence of efficacy in clinical trials of varying design, there are no approved treatments for NASH, and published trials are often too divergent to allow meaningful comparisons. There is thus a lack of established noninvasive, point-of-care diagnostics and approved treatment on one hand and a substantial population burden of disease on the other. These provide the rationale for developing consensus on key endpoints and clinical trial design for NASH. Conclusion: This article summarizes the consensus arrived at a meeting of the American Association for the Study of Liver Diseases on the key endpoints and specific trial design issues that are germane for development of diagnostic biomarkers and treatment trials for NASH. (HEPATOLOGY 2011;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Self-citationPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · Radiology · doi:10.1148/radiol.2261021292 · Cited by 3,215
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citationMoreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,020
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
“Despite the high variability of at least two of the three components of NAS, reported already in the original publication,(13) and limited data on the ability of NAS to predict disease outcome, NAS is recommended to be used to define and quantify disease activity in clinical trials of NAFLD/NASH.(14) Because of the ve…”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationBoursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
“As recently recommended,((20)) NASH was defined as the presence of each of the three following conditions: steatosis grade 1; lobular”
BackgroundNonalcoholic Steatohepatitis: A Review
Sheka, A. C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020) · JAMA · doi:10.1001/jama.2020.2298 · Cited by 1,379
Mitochondrial dynamics in health and disease: mechanisms and potential targets
Chen, W., Zhao, H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01547-9 · Cited by 1,306
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.-L., Basdevant, A., Paradis, V., Tordjman, J., & Clement, K. (2012) · Hepatology · doi:10.1002/hep.25889 · Cited by 903
Non-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 751
Sumida, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.475 · Cited by 689
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 585
Self-citationNon-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
Milić, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9330 · Cited by 583
Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease
Cermelli, S., Ruggieri, A., Marrero, J. A., Ioannou, G. N., & Beretta, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023937 · Cited by 564
Gut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525
Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., & Ratziu, V. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.027 · Cited by 522
Self-citationCassinotto, C., Boursier, J., de Lédinghen, V., Lebigot, J., Lapuyade, B., Cales, P., Hiriart, J., Michalak, S., Bail, B. L., Cartier, V., et al. (2016) · Hepatology · doi:10.1002/hep.28394 · Cited by 521
LaBrecque, D. R., Abbas, Z., Anania, F., Ferenci, P., Khan, A. G., Goh, K.-L., Hamid, S. S., Isakov, V., Lizarzabal, M., Peñaranda, M. M., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000116 · Cited by 519
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15539 · Cited by 486
The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Davison, B. A., Harrison, S. A., Cotter, G., Alkhouri, N., Sanyal, A., Edwards, C., Colca, J. R., Iwashita, J., Koch, G. G., & Dittrich, H. C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.025 · Cited by 448
Self-citationEpidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.040 · Cited by 426
Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research
Kleiner, D., & Brunt, E. (2012) · Seminars in Liver Disease · doi:10.1055/s-0032-1306421 · Cited by 402
Self-citationStefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Lee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2021) · Liver International · doi:10.1111/liv.14669 · Cited by 378
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Brown, G. T., & Kleiner, D. E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.008 · Cited by 363
Self-citationChen, Y.-M., Liu, Y., Zhou, R.-F., Chen, X.-L., Wang, C., Tan, X.-Y., Wang, L.-J., Zheng, R.-D., Zhang, H.-W., Ling, W.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep19076 · Cited by 358
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Pathology of non‐alcoholic fatty liver disease
Bedossa, P. (2017) · Liver International · doi:10.1111/liv.13301 · Cited by 322
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Self-citationNon-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 302
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 292
Bril, F., Barb, D., Portillo‐Sanchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. (2017) · Hepatology · doi:10.1002/hep.28985 · Cited by 288
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 287
Spengler, E. K., & Loomba, R. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 284
Yang, L., Roh, Y. S., Song, J., Zhang, B., Liu, C., Loomba, R., & Seki, E. (2014) · Hepatology · doi:10.1002/hep.26698 · Cited by 275
Mikolasevic, I., Orlic, L., Franjic, N., Hauser, G., Stimac, D., & Milic, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7236 · Cited by 273
Secondary causes of nonalcoholic fatty liver disease
Kneeman, J. M., Misdraji, J., & Corey, K. E. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11430859 · Cited by 268
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
Self-citationFarnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., Hanouneh, I. A., Alhaddad, R., & Alkhouri, N. (2016) · Hepatology International · doi:10.1007/s12072-015-9679-0 · Cited by 166
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis
Yu, J., Zhu, C., Wang, X., Kim, K., Bartolome, A., Dongiovanni, P., Yates, K. P., Valenti, L., Carrer, M., Sadowski, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1692 · Cited by 132
Self-citationCheng, S., Ge, J., Zhao, C., Le, S., Yang, Y., Ke, D., Wu, N., Tan, X., Zhang, X., Du, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16159-x · Cited by 127
Guo, W., Tian, W., Lin, L., & Xu, X. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108487 · Cited by 126
Machine learning enables new insights into genetic contributions to liver fat accumulation
Haas, M. E., Pirruccello, J. P., Friedman, S. N., Wang, M., Emdin, C. A., Ajmera, V. H., Simon, T. G., Homburger, J. R., Guo, X., Budoff, M., et al. (2021) · Cell Genomics · doi:10.1016/j.xgen.2021.100066 · Cited by 118
Vuppalanchi, R., Jain, A. K., Deppe, R., Yates, K., Comerford, M., Masuoka, H. C., Neuschwander-Tetri, B. A., Loomba, R., Brunt, E. M., Kleiner, D. E., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.010 · Cited by 116
Self-citationBril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease
VanWagner, L. B., Ning, H., Allen, N. B., Ajmera, V., Lewis, C. E., Carr, J. J., Lloyd-Jones, D. M., Terrault, N. A., & Siddique, J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.012 · Cited by 74
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice
Yang, L., Miura, K., Zhang, B., Matsushita, H., Yang, Y. M., Liang, S., Song, J., Roh, Y. S., & Seki, E. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.12.004 · Cited by 62
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Cassinotto, C., Boursier, J., Paisant, A., Guiu, B., Irles‐Depe, M., Canivet, C., Aube, C., & de Ledinghen, V. (2021) · Hepatology · doi:10.1002/hep.31655 · Cited by 55
Marin‐Alejandre, B. A., Cantero, I., Perez‐Diaz‐del‐Campo, N., Monreal, J. I., Elorz, M., Herrero, J. I., Benito‐Boillos, A., Quiroga, J., Martinez‐Echeverria, A., Uriz‐Otano, J. I., et al. (2021) · Liver International · doi:10.1111/liv.14818 · Cited by 54
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
Finer, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14569 · Cited by 45
Hernandez, G. V., Smith, V. A., Melnyk, M., Burd, M. A., Sprayberry, K. A., Edwards, M. S., Peterson, D. G., Bennet, D. C., Fanter, R. K., Columbus, D. A., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00344.2019 · Cited by 44
Effect of intragastric balloons on liver enzymes: A systematic review and meta-analysis
Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4178-2 · Cited by 43
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.028 · Cited by 41
Self-citationSun, B. L., Sun, X., Kempf, C. L., Song, J. H., Casanova, N. G., Camp, S. M., Reyes Hernon, V., Fallon, M., Bime, C., Martin, D. R., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201972rr · Cited by 35
Ke, Y., Liu, S., Zhang, Z., & Hu, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01481-1 · Cited by 28
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27
Self-citationFrom NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
Collagen-targeted molecular imaging in diffuse liver diseases
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C., & Caravan, P. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02677-2 · Cited by 14
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Metadata
- Authors
- Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A.
- Venue
- Hepatology
- Published
- 2011-07
- Volume
- 54
- Issue
- 1
- Pages
- 344-353
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2120056458
- Cited by
- 750
- References
- 61
- FWCI
- 30.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.